
A new NIH report on cancer in people aged 20 to 49 shows that while rates are declining, women and minorities still face significant rates.

A new NIH report on cancer in people aged 20 to 49 shows that while rates are declining, women and minorities still face significant rates.

Oncologists recognize the potential of artificial intelligence (AI) in improving the quality of care and patient outcomes according to new research.

In the three decades since its passage, Stark Law has become one of the most significant sources of regulatory burden on physicians and, ultimately, for Medicare beneficiaries.

FDA cleared alpelisib (Piqray), the first PI3K inhibitor to treat breast cancer, to be used in combination with fulvestrant (Faslodex).

FDA granted market authorization for a non-invasive, smartphone device that offers respite from migraines.

New study compares every state using data like opioid prescriptions and overdose rates to determine where drug problems hit hardest.

From drug price concerns to the evolving role of PBMs to the influence of specialty pharmaceuticals, what healthcare executives think about the future of pharmacy.

Here are five surprising ways to tailor experiences so patients adopt healthier behaviors when faced with chronic conditions like diabetes, heart disease, cancer, and COPD.

How will payers, providers, and patients respond when a $2 million drug drops into the market?

The 2018 oncology drug market had a record number of new treatments and continued a trend of growth.

A new report shows that the new open enrollment rules are leading to increased Medicare Advantage uptake.

Healthcare costs remain the most important financial problem facing American families, according to a Gallup poll.

The prevalence of diagnosed diabetes in the United States has remained stable during the past eight years, even as obesity rates climb.

New definition of burnout to be included in forthcoming ICD-11.

As Best Buy extends its reach into health technologies and services, a unique opportunity may open up for providers.

In the first of many similar cases, the trial of Oklahoma versus Johnson & Johnson could frame who is to blame for the opioid epidemic.

With a more than $2 million price tag, how are payers going to deal with the recently approved Zolgensma?

The new plan could affect all of healthcare and could radically change contract provider agreements.

What the development means for healthcare.

A majority of healthcare workers are women, but few make it to leadership roles. Here are the surprising reasons behind the gap.

Where plans and patients are spending the most money on medications.

Why hospital pharmacists are playing an increasingly-large role in patient care and why their involvement can boost medication outcomes and reduce errors.

Express Scripts, a Cigna company, plans to launch the industry's first stand-alone digital health formulary.

Surgery shouldn’t be the first step when considering treatment. Analytics can help the determine the best path that leaves patients healthier and payers with fewer costs.

FDA approved some important new therapies, including the first anticoagulant for children, an injectable for diabetic retinopathy, and a treatment for renal cell carcinoma.

Top leaders share simple ways to cultivate patient loyalty.

A new study shows that members who enroll in Medicare Advantage plans may have lower spending.

A new RAND study uncovers significant differences between healthcare costs paid by privately insured patients and those paid out by Medicare.

Offering multiple, segmented approaches to health can confuse consumers-and reduce engagement. Instead, focus efforts on comprehensive solutions.

Healthcare treatment compliance can be difficult for patients facing other issues like unaddressed SDOH problems or mental health diseases. Here are four ways to engage those members.